BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) has today announced the launch of TASCENSO ODT, its first product to treat MS patients in the US. The launch ensures MS patients in the US currently benefitting from Gilenya, or generic fingolimod, can access appropriate patient support services alongside the bioequivalent, non-generic, TASCENSO ODT. Gilenya patient support services are scheduled to be withdrawn on March 31st 2023.1,2,3
Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA’s Approval of TASCENSO ODT® (fingolimod)
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of SAJAZIR™ (icatibant) Injection, a new treatment option for patients affected by Hereditary Angioedema (HAE) approved by the US Food and Drug Administration (FDA).
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) is pleased to announce the launch of its Boston-based support platform for rare disease patients, Cycle Vita™.
RadioMedix’s Detectnet (copper Cu 64 dotatate injection) has been approved for the detection of somatostatin receptor‒positive neuroendocrine tumors (NETs) in adult patients during imaging with positron emission tomography.
BOSTON--(BUSINESS WIRE)--Cycle Pharmaceuticals is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the once daily dosing of NITYR®.
Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, today announced that it has executed a definitive agreement for a $25 million credit facility with Deutsche Bank AG. This strategic financing allows Cycle to build on the success of NITYR® (nitisinone) Tablets, which treats patients with the rare genetic metabolic disease, hereditary tyrosinemia type 1. Cycle’s mission is to utilise the latest pharmaceutical technologies to deliver best-in-class drug treatments to better serve rare genetic disease patients.
Midlands Medictech company Medherant has signed a partnership agreement with Cambridge-based Cycle Pharmaceuticals to develop multiple new products using Medherant technology developed by University of Warwick chemistry researchers.
CAMBRIDGE & COVENTRY, England--(BUSINESS WIRE)--Cycle Pharmaceuticals Ltd (Cycle) and Medherant Ltd (Medherant) are pleased to announce that they have signed an agreement to develop and commercialize multiple products using the TEPI Patch® technology.